Clinical trials: Drug Survival
Intensive Care Medicine
Predictive Value of the mNutric Score and Survival Analysis in Critically Ill Patients Hospitalised in the Intensive Care Unit
Our study is an observational study and the follow-up hematological tests of patients in the intensive care unit will be recorded during their first admission.
- Trial name
- NCT06912204
- Where
- Turkey (Türkiye)
- Volunteers
- 85 people
- Sponsor
- Amasya University
Neoplasms, Lung, Carcinoma, Non-Small Cell Lung
A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations
Objective: the objective of this study in china is to clarify, whether the overall survival is different between previously untreated stage IIIB/IV lung adenocarcinoma with EGFR mutations receiving first-line erlotinib plus…
- Conditions
- Neoplasms, Lung, Carcinoma, Non-Small Cell Lung, Drug Therapy, Genes, EGFR
- Trial name
- NCT01131429
- Testing
- Erlotinib, Docetaxel, Cisplatin
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Chinese PLA General Hospital
Chronic Lymphocytic Leukemia (CLL)
A Study Evaluating the Impact of Venetoclax on the Quality of Life for Subjects With Relapsed (Your Cancer Has Come Back) or Refractory (no Response to Previous Cancer Treatments) Chronic Lymphocytic Leukemia (CLL) While Receiving Venetoclax Monotherapy (a Single Agent).
The purpose of this open-label, single-arm study was to evaluate the impact of venetoclax on the quality of life of participants including those with with relapsed/refractory (R/R) chronic lymphocytic leukemia (CLL; a type of…
- Trial name
- VENICE II (NCT02980731)
- Testing
- Venetoclax
- Where
- 33 sites in Argentina, Australia and 8 more
- Volunteers
- 210 people
- Sponsor
- AbbVie
Liver Transplantation, Immune Tolerance
Immune Tolerance Induction After Liver Transplantation
This clinical trial is being conducted to help liver transplant recipients safely discontinue toxic immunosuppressive drugs years after surgery.
- Conditions
- Liver Transplantation, Immune Tolerance, Immune Tolerance/Drug Effects, Graft Survival
- Trial name
- iTILT (NCT07269041)
- Testing
- Donor Hematopoietic Stem and Progenitor Cell Infusion
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- University of California, Los Angeles
Breast Cancer
Study to Compare Overall Survival in Medicare Patients With Metastatic Breast Cancer Treated With a Medicine Called Palbociclib in Combination With Aromatase Inhibitor and Aromatase Inhibitor by Itself.
A retrospective study of de-identified (to preserve patient privacy) patient information from the SEER-Medicare Database to compare overall survival of first line palbociclib + aromatase inhibitor (AI) therapy versus AI therapy…
- Trial name
- NCT06086340
- Testing
- Palbociclib, Aromatase Inhibitor
- Where
- United States
- Volunteers
- 779 people
- Sponsor
- Pfizer
Implantable Cardioverter Defibrillators, CRT-D Cardiac Resynchronization Therapy Defibrillator
LONGEVITY Study. Evaluation of the Device and Battery Longevity of Boston Scientific Market-released ICD and CRT-D Devices
The study is to determine the rate and cause of device replacements at 5 years post-implantation. It will assess the battery and device longevity of the Implantable Cardioverter Defibrillators (ICD) and CRT-D Cardiac…
- Trial name
- NCT02091011
- Where
- 80 sites in United States, Canada and 6 more
- Volunteers
- 1,600 people
- Sponsor
- Boston Scientific Corporation
Bile Duct Cancer, Biliary Cancer
Combination of Trametinib (MEK Inhibitor) and Hydroxychloroquine (HCQ) (Autophagy Inhibitor) in Patients With KRAS Mutation Refractory Bile Tract Carcinoma (BTC).
Background: Bile duct cancer is cancer of the slender tubes of the biliary tract. These tubes carry bile through the liver. Such cancer tumors often have an abnormal or mutated gene.
- Conditions
- Bile Duct Cancer, Biliary Cancer, Biliary Tract Neoplasms, Cholangiocarcinoma
- Trial name
- NCT04566133
- Testing
- Trametinib, Hydroxychloroquine
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer, Hormone Dependent Neoplasms
A Web-Based Tool to Improve Breast Cancer Survivorship
The purpose of this study is to examine the efficacy of a psychosocial eHealth intervention on the proposed primary outcomes, hormone therapy adherence and health related quality of life (HRQoL), in breast cancer survivors.
- Conditions
- Breast Cancer, Hormone Dependent Neoplasms, Adherence to Hormone Therapy
- Trial name
- NCT03849573
- Testing
- "OncoTool" Intervention (MBSR + HT education), "Oncotool" Control (health +HT education)
- Where
- United States
- Volunteers
- 84 people
- Sponsor
- Northwestern University
Sepsis
Implementation and Effectiveness of Engagement and Collaborative Management to Proactively Advance Sepsis Survivorship
The purpose of this study is to evaluate if implementation of the Sepsis Transition and Recovery (STAR) program within a large healthcare system will improve outcomes for high-risk patients with suspected sepsis, while…
- Trial name
- ENCOMPASS (NCT04495946)
- Testing
- Sepsis Transition and Recovery (STAR) program, Usual care
- Where
- United States
- Volunteers
- 3,894 people
- Sponsor
- Wake Forest University Health Sciences
HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine
Shuganhuazhuo Formula for Advanced Hepatocellular Carcinoma With Damp-Heat Syndrome
Primary liver cancer is a malignant tumor with a very poor prognosis. Hepatocellular carcinoma(HCC) accounts for approximately 80% of cases.
- Conditions
- HCC - Hepatocellular Carcinoma, Chinese Herbal Medicine, ICG (Indocyanine Green), Overall Survival (All-cause Mortality)
- Trial name
- DAWNbreak-120 (NCT07691645)
- Testing
- Shuganhuazhuo Formula, Targeted therapy, Immunotherapy
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Xiang-Qian
Moderate-to-severe Plaque Psoriasis
Secukinumab Drug Survival, Effectiveness and Tolerability in Pediatric Patients With Psoriasis
Multicenter, non-interventional, cohort study in pediatric patients with moderate to severe plaque-type psoriasis. Retrospective data collection is planned at patients' inclusion.
- Trial name
- SPARROW (NCT06142357)
- Testing
- Secukinumab
- Where
- 16 sites in Russia
- Volunteers
- 199 people
- Sponsor
- Novartis Pharmaceuticals
Prostate Cancer, Prostate Cancer Recurrent
Metastasis-directed Therapy for Oligorecurrent Prostate Cancer
The aim is to investigate whether the addition of short-term androgen deprivation therapy (ADT) during 1 month or short-term ADT during 6 months together with an androgen receptor targeted therapy (ARTA) to metastasis-directed…
- Conditions
- Prostate Cancer, Prostate Cancer Recurrent, Prostate Cancer Metastatic, Metastatic Cancer
- Trial name
- SPARKLE (NCT05352178)
- Testing
- Radiotherapy (SBRT) and/or surgery (metastasectomy), Androgen deprivation therapy, Androgen receptor targeted therapy
- Where
- Belgium
- Volunteers
- 873 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Atopic Dermatitis
Drug Survival of Target Therapies in Atopic Dermatitis
This is an observational study with drug to evaluate the drug survival of approved target therapies in atopic dermatitis. Patients affected by moderate-severe atopic dermatitis who will start therapy with approved target drugs…
- Trial name
- VADRUDA (NCT06882148)
- Testing
- target therapies (biological drug, small molecules)
- Where
- Italy
- Volunteers
- 1,167 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Hepatocellular Carcinoma
Comparison of Two Solvents Used With Chemotherapy Agent for Transarterial Chemoembolization of Hepatocellular Carcinoma
TACE is considered the standard treatment for unresectable HCC and is widely used as a palliative treatment. However there is no consensus of the protocol of TACE.One of the variation is does the stability of the suspension by…
- Trial name
- NCT01259414
- Testing
- Solvent with specific gravity less than lipiodol, Solvent with specific gravity equivalent to lipiodol
- Where
- China
- Volunteers
- 812 people
- Sponsor
- Sun Yat-sen University
Metastatic Prostate Cancer
The Present Study Aims to Compare Patients Who Receive the Investigational Product (177Lu-DOTA-rosopatamab) Plus Standard of Care, in Comparison to Standard of Care Only
This multinational, multicenter, prospective, randomized, controlled, open label Phase 3 study is designed to investigate and confirm the benefits and risks associated with the PSMA-targeted antibody, 177Lu DOTA rosopatamab…
- Trial name
- NCT04876651
- Testing
- 177Lu-DOTA-rosopatamb, Standard of Care
- Where
- 6 sites in Australia, New Zealand
- Volunteers
- 16 people
- Sponsor
- Telix Pharmaceuticals (Innovations) Pty Ltd
Melanoma
Lenalidomide (Revlimid) to Treat Advanced Ocular Melanoma
This study will test whether an experimental drug called Revlimid (lenalidomide) can reduce tumor size and prolong survival in patients with metastatic melanoma (melanoma that has spread beyond the original tumor site).
- Trial name
- NCT00109005
- Testing
- Revlimid
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Coronary Heart Disease, Coronary Restenosis
Study of Oral Rapamycin Plus Bare Metal Stents vs Drug Eltuting Stents
In a previous randomized comparison oral sirolimus plus bare metal stent compared to bare metal stent implantation alone demonstrated at one year of follow up a significant reduction of angiographic and clinical parameters of…
- Trial name
- ORAR III (NCT00552669)
- Testing
- Oral sirolimus, Drug Eluting stent
- Where
- 3 sites in Argentina
- Volunteers
- 200 people
- Sponsor
- Centro de estudios en Cardiologia Intervencionista
Melanoma (Skin Cancer), Nevi and Melanomas
Precision Medicine for L/GCMN and Melanoma 1
The primary objective of this study is to create a highly multidimensional and multicentric database for melanoma that encompasses cohorts of children, adolescent and young adults.
- Trial name
- Precis-mel 1 (NCT06608420)
- Testing
- Gradient Boosting Survival Analysis (GBSA),, Concordance index
- Where
- Spain
- Volunteers
- 6,000 people
- Sponsor
- Fundacion Clinic per a la Recerca Biomédica
Prostate Cancer
Prostate Specific Membrane Antigen (PMSA)-Based PET Imaging of High Risk Prostate Cancer
Background: People with prostate cancer usually have their cancer imaged with a CT scan and bone scan. They then have their prostate gland removed.
- Trial name
- NCT03976843
- Testing
- 18F-DCFPyL
- Where
- 6 sites in United States
- Volunteers
- 175 people
- Sponsor
- National Cancer Institute (NCI)
Chronic Rejection of Liver Transplant
Safety Study of Using Regulatory T Cells Induce Liver Transplantation Tolerance
The first trial will involve the generation of donor alloantigen-specific CD4+CD25+ Tregs from peripheral blood of pre-transplant patients, the administration of the CD4+CD25+ Tregs (1 x 106 cells/kg) at several intervals (for…
- Trial name
- Treg (NCT01624077)
- Testing
- Regulatory T cells
- Where
- China
- Volunteers
- 1 people, healthy volunteers welcome
- Sponsor
- Nanjing Medical University